Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $77.22M |
| Gross Profit (TTM) | $-182.81M |
| EBITDA | $-316.80M |
| Operating Margin | -349.80% |
| Return on Equity | -167.70% |
| Return on Assets | -31.30% |
| Revenue/Share (TTM) | $0.88 |
| Book Value | $1.22 |
| Price-to-Book | 19.95 |
| Price-to-Sales (TTM) | 12.51 |
| EV/Revenue | 6.11 |
| EV/EBITDA | -2.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.50% |
| Shares Outstanding | $88.96M |
| Float | $70.60M |
| % Insiders | 1.43% |
| % Institutions | 99.70% |
Volatility is currently contracting
The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
– KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –
– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 3, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026. Kura's management will host a webcast and conference call at 4:30 p.m.
Kura Oncology NASDAQ: KURA presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma (RCC) that had progressed after prior treatment, including immunotherapy.
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –
Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KURA and any ticker you trade — then tracks every position and per-strategy win rate.
